in oncogenes and genes-suppressors can lead to developing of cancer by alteration of intracellular metabolism, proliferation, cell death and cellular interplay. Such cell's modifications are responsible for growth of tumor.
have clinical significance for progress of disease, associated with effectiveness of different treatment options and, therefore, are regarded as biomarkers.
which has definite prognostic and predictive meaning. Today there are a lot of drugs on market, which target specific molecular changes (biomarkers) in cancer cells (target treatment). Furthermore, recent investigations demonstrate that effectiveness of standard chemotherapy also depends on molecular profile of tumor
not only in necessity of developing new therapeutic agents, but also in problems of sensible using different drugs for every patient and overcoming resistance to various treatment options.
a new therapeutic approach involving the use of an individual’s genetic and epigenetic information, environment conditions and patient’s lifestyle to tailor drug therapy or preventive care. In oncology personalized treatment includes using tumor's molecular profile for diagnosis, creation of therapy plan and assessment of treatment effectiveness.
Consultation includes: indications for molecular-genetic analysis; collection of data about patient and anamnesis morbi; collection of samples or analysis (biopsy and liquid biopsy)
Histological confirmation of diagnosis
Development of molecular profile (NGS; IHC)
Bioinformatic and system biology processing of data
Complex conclusion: individual molecular profile, potential sensitive\resistance to different treatment options, clinical trials, mechanisms of cancerogenesis
Confirmation of diagnosis
Development of molecular profile
Processing of data
includes knowledge about all clinically significant biomarkers, clinical trials, pharmacogenomics and signal pathways. Database regularly updated from approved sources. All data is stored in cloud storage and good guarded.
to provide complex analysis of different types of biomarkers, including data about anamnesis morbi, histological characteristics of tumor, NGS, IHC and other diagnostic options
was given to the most accurate detection of molecular alterations by using of the latest versions of bioinformatic software. By using of neural networks and deep learning we develop proprietary algorithm for analysis of associations between molecular profile of tumor and potential effectiveness of treatment.
implements the principles of precision medicine and provides oncologists with wide summary of data for the best treatment option.
Director for Scientific Development
Mentor, Oncologist, Surgeon
In our company we gather a team of specialists from different clusters to create a multidisciplinary approach to the diagnosis and treatment of cancer.